ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups Meet With NCI to Discuss Plan to use Rosenberg’s Regimen At Member Institutions

December 13, 1985

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014

Test Of HHS Secretary’s Remarks On cancer Mortality Rate Findings

November 22, 1996

In Congress: $135 Million Expected For DOD Breast Cancer Research Program

July 24, 1998

NCI Chief Operating Officer Lawrence Ray To Retire

April 24, 2009

Intergroup 5-FU/Levamisole Study Positive Enough Now To End Untreated Control Arms

September 22, 1989